{"brief_title": "Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)", "brief_summary": "The purpose of this study is to evaluate the long-term safety of AVP-923 in the treatment of Involuntary Emotional Expression Disorder (IEED) also known as Pseudobulbar Affect (episodes of uncontrolled crying and/or laughter).", "detailed_description": "This is an \"open label\" study which means there is no placebo group. Each subject enrolled into the study will receive AVP-923.", "condition": "Traumatic Brain Injury", "intervention_type": "Drug", "intervention_name": "AVP-923", "criteria": "Inclusion Criteria: - 18 to 75 years of age, inclusive - Clinical diagnosis of PBA (pseudobulbar affect) - If female, must not be pregnant or breast feeding Exclusion Criteria: - Sensitivity to quinidine or any opiate drugs - Current or prior history of major psychiatric disturbance - Currently participated in a trial within the past 30 days", "gender": "All", "minimum_age": "18 Years", "maximum_age": "80 Years", "healthy_volunteers": "No", "id": "NCT00056524.xml"}